Lv1
50 积分 2024-01-04 加入
HER2-Positive Metastatic Colorectal Cancer
5小时前
待确认
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
4个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
4个月前
已完结
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
8个月前
已完结
Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study
9个月前
已关闭
Adjuvant and neoadjuvant therapies for hepatocellular carcinoma
10个月前
已完结
[Chinese expert consensus on neoadjuvant therapy for hepatocellular carcinoma (2023 edition)]
10个月前
已完结
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
10个月前
已完结
皖公网安备34019202002308
